Join our daily and weekly newsletters for the latest updates and exclusive content on industry-leading AI coverage. Learn More Generative AI has become a key piece of infrastructure in many industries, and healthcare is no exception. Yet, as organizations like GSK push the boundaries of what generative AI can achieve, they face significant challenges — particularly when it comes to reliability. Hallucinations, or when AI models generate incorrect or fabricated information, are a persistent problem in high-s ...

Company Overview - GSK is a global biopharma company focused on the prevention and treatment of disease [5] - The company demerged its consumer business three years ago to create a dedicated biopharma company with a clear focus on benefiting patients and shareholders [3] Financial Performance - For the full year 2024, GSK confirmed sales growth guidance of 7% to 9% and core operating profit growth of 11% to 13% [2] - In the first nine months of 2024, GSK delivered 9% sales growth and 19% core operating profit growth, reflecting strong momentum in Specialty Medicines and overall portfolio resilience [5] Strategic Outlook - GSK expects to secure five product approvals in 2025 [2] - The company has high confidence in delivering the growth outlooks set for 2026 and 2031 [2]

Key Points Company and Industry Overview 1. **GSK as a Global Biopharma Company**: GSK is a global biopharma company focused on the prevention and treatment of disease [3]. 2. **Demerger and Biopharma Focus**: GSK demerged its consumer business three years ago, creating a dedicated biopharma company with a clear focus on benefiting patients and shareholders [2]. Financial Performance 3. **2024 Sales and Profit Growth**: In the first nine months of 2024, GSK delivered 9% sales growth and 19% core operating profit growth [3]. 4. **Full-Year 2024 Guidance**: GSK confirmed its guidance for full-year 2024, expecting sales growth of 7% to 9% and core operating profit growth of 11% to 13% [5]. Product Approvals and Outlook 5. **Product Approvals and Growth Outlook**: GSK expects to secure five product approvals in the coming year and remains highly confident in delivering the growth outlooks set for 2026 and 2031 [5].

GSK plc (GSK) announced that the FDA has granted a Breakthrough Therapy Designation to its investigational B7-H3-targeted antibody-drug conjugate (ADC), GSK5764227 (GSK’227), for the treatment of relapsed or refractory osteosarcoma in adult patients whose disease progressed on at least two prior lines of therapy.The FDA grants Breakthrough Therapy designation to expedite the development and review of therapies for severe or life-threatening diseases where preliminary clinical evidence shows that the therapy ...

GSK plc’s (GSK) HIV subsidiary, ViiV Healthcare announced that the Europe Medicines Agency’s (“EMA”) Committee for Medicinal Products for Human Use (“CHMP”) has rendered a positive opinion recommending marketing authorization for its new long-acting HIV regimen.ViiV Healthcare is a global specialist HIV company, majorly owned by GSK with Pfizer (PFE) and Shionogi as shareholders.ViiV Healthcare was formed by GSK and Pfizer in 2009.The CHMP recommended marketing authorization to Vocabria (cabotegravir long-a ...

GSK (GSK) stock has declined 20.2% in the past three months compared with a decrease of 12.3% for the industry. The stock has also underperformed the sector and the S&P 500 index, as seen in the chart below. The stock is also trading below its 200 and 50-day moving averages.GSK Stock Underperforms Industry, Sector and S&PImage Source: Zacks Investment ResearchGSK enjoys a strong position in HIV and Vaccines therapeutic areas. The spin-off of the Consumer unit in 2022 has allowed it to focus on drug developm ...

GSK plc (GSK) announced that the European Commission (EC) has approved a single-vial, fully liquid presentation of its meningococcal vaccine, Menveo (MenACWY) for active immunization in children aged two years, adolescents as well as adults.The single-vial, fully liquid presentation of Menveo is likely to simplify the vaccination process against invasive meningococcal disease (IMD) caused by bacterial serogroups A, C, W and Y.The fully liquid presentation of the vaccine will help healthcare providers with a ...

GSK plc (GSK) announced that the FDA accepted its biologics license application (BLA) seeking approval for the Blenrep (belantamab mafodotin) combination therapy to treat relapsed or refractory multiple myeloma (RRMM) for review.The BLA seeks the approval of Blenrep in combination with J&J’s Velcade (bortezomib) plus dexamethasone (BorDex) or Bristol Myers’ Pomalyst (pomalidomide) plus dexamethasone (PomDex) for the treatment of patients with multiple myeloma who have received at least one prior line of the ...

GSK plc (GSK) announced positive headline data from the phase III GLISTEN study, which is evaluating its investigational targeted inhibitor of the ileal bile acid transporter (IBAT), linerixibat, for treating adult patients with cholestatic pruritus associated with primary biliary cholangitis (PBC).The global GLISTEN study met its primary endpoint by showing that treatment with linerixibat led to a statistically significant improvement in monthly itch score as compared with placebo over 24 weeks.Per managem ...

About this content About Josh Lamb After graduating from the University of Kent in the summer of 2022 with a degree in History, Josh joined Proactive later that year as a journalist in the UK editorial team. Josh has reported on a range of areas whilst at Proactive, including energy companies during a time of global crisis, aviation and airlines as the sector recovers from the pandemic, as well as covering economic, social and governance issues. Read more About the publisher Proactive financial news and ...